NEOSH-101(NEOSH-101) - _专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点-

作用机制-

治疗领域

皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

男性雄激素源性脱发雄激素脱发

原研机构

Neosil, Inc.

在研机构-

非在研机构

Neosil, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 NEOSH-101 相关的临床试验

NCT00471510 / Unknown status临床2期

A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men

The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia). Four equally sized treatment groups (35 men each) will receive either NEOSH101 0.5%, NEOSH101 1.0%, NEOSH101 2.0% or placebo. A 12-week observation period will follow the treatment period.

开始日期2007-05-01

申办/合作机构

Neosil, Inc.

EUCTR2007-000511-28-DE / Not yet recruitingN/A

A Phase 2 Multicenter, Randomized, Placebo-Controlled, Double-Blind Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men - Alopecia

开始日期2007-04-20

申办/合作机构

Neosil, Inc.

NCT00418730 / Completed临床2期

A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men

The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.

开始日期2007-01-01

申办/合作机构

Neosil, Inc.

100 项与 NEOSH-101 相关的临床结果

登录后查看更多信息

100 项与 NEOSH-101 相关的转化医学

登录后查看更多信息

100 项与 NEOSH-101 相关的专利（医药）

登录后查看更多信息

100 项与 NEOSH-101 相关的药物交易

登录后查看更多信息